1. Scrip
  2. >>R&D
  3. >>Clinical Trials

AbbVie Ups Its IBD Game With Latest Crohn’s Data For Rinvoq

Last Of Three Phase III Readouts Also Positive

 
• By Mandy Jackson

The leader in inflammatory bowel disease via Humira, AbbVie awaits a US FDA decision in June for Skyrizi in Crohn’s disease and plans to add a Crohn’s indication to Rinvoq’s ulcerative colitis approval.

Chain of arrows blocks
Crohn's disease is an important building block in AbbVie's Rinvoq strategy • Source: Shutterstock

AbbVie Inc. has a long leadership position in autoimmune diseases due to its top-selling TNF inhibitor Humira (adalimumab) and continues to build on its legacy in inflammatory bowel disease (IBD) via the newer blockbusters Skyrizi (risankizumab) and Rinvoq (upadacitinib). Approved in the US for ulcerative colitis in March, the company now has the data it needs to seek approvals for Rinvoq in Crohn’s disease while it awaits a US Food and Drug Administration decision in June that would make Crohn’s the first IBD indication for Skyrizi.

AbbVie reported top-line results on 11 May from the Phase III U-ENDURE clinical trial testing the JAK1 inhibitor Rinvoq versus placebo for one year in adults with moderate to severe...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Clinical Trials

ASCO: IO Continues Climb To Earlier Use With AstraZeneca’s MATTERHORN, BMS’s NIVOPOSTOP

 
• By Mary Jo Laffler

Data presented at ASCO supports use of AZ’s Imfinzi for perioperative gastric cancer and BMS’s Opdivo for adjuvant treatment of head and neck cancer.

Regeneron Buys Tirzepatide-Like Product With Eye On Muscle-Preserving Combinations

 
• By Jessica Merrill

Regeneron is bringing in its own GIP/GLP-1 agonist, establishing a path to develop proprietary obesity drug combinations with its internal muscle-sparing drugs.

ASCO: DESTINY-Breast09 Strong, But May Need Mature OS Data To Change Practice

 
• By Alaric DeArment

Data from AstraZeneca/Daiichi’s breast cancer trial showed positive PFS, but some oncologists are waiting for confirmation of statistically significant OS benefit.

Sanofi Plays It Safer With Blueprint Buy After Bumpy 2025

 
• By Kevin Grogan

But the French major is still keen on early-stage M&A.

More from R&D